Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD6738 and Durvalumab in Metastatic Gastric Cancer and Melanoma
NCT03780608Phase 2Unknown
- Sponsor
- Samsung Medical Center
- Start
- Jul 2019
- Primary completion
- Dec 2022
- Countries
- 1
01
Overview
A Phase 2 trial of ceralasertib in gastric adenocarcinoma, Malignant Melanoma (MM), sponsored by Samsung Medical Center. Status: unknown.
02
Drugs
ceralasertib
03
Conditions
gastric adenocarcinomaMalignant Melanoma (MM)
Beyond the preview
Go deeper on NCT03780608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03780608.